International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program
Open Access
- 1 July 1998
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 36 (7) , 1886-1889
- https://doi.org/10.1128/jcm.36.7.1886-1889.1998
Abstract
An international program of surveillance of bloodstream infections (BSIs) in the United States, Canada, and South America between January and December 1997 detected 306 episodes of candidemia in 34 medical centers (22 in the United States, 6 in Canada, and 6 in South America). Eighty percent of the BSIs were nosocomial and 50% occurred in patients hospitalized in an intensive care unit. Overall, 53.3% of the BSIs were due to Candida albicans , 15.7% were due to C. parapsilosis , 15.0% were due to C. glabrata , 7.8% were due to C. tropicalis , 2.0% were due to C. krusei , 0.7% were due to C. guilliermondii , and 5.8% were due to Candida spp. However, the distribution of species varied markedly by country. In the United States, 43.8% of BSIs were due to non- C. albicans species. C. glabrata was the most common non- C. albicans species in the United States. The proportion of non- C. albicans BSIs was slightly higher in Canada (47.5%), where C. parapsilosis , not C. glabrata , was the most common non- C. albicans species. C. albicans accounted for 40.5% of all BSIs in South America, followed by C. parapsilosis (38.1%) and C. tropicalis (11.9%). Only one BSI due to C. glabrata was observed in South American hospitals. Among the different species of Candida , resistance to fluconazole (MIC, ≥64 μg/ml) and itraconazole (MIC, ≥1.0 μg/ml) was observed with C. glabrata and C. krusei and was observed more rarely among other species. Isolates of C. albicans , C. parapsilosis , C. tropicalis , and C. guilliermondii were all highly susceptible to both fluconazole (99.4 to 100% susceptibility) and itraconazole (95.8 to 100% susceptibility). In contrast, 8.7% of C. glabrata isolates (MIC at which 90% of isolates are inhibited [MIC 90 ], 32 μg/ml) and 100% of C. krusei isolates were resistant to fluconazole, and 36.9% of C. glabrata isolates (MIC 90 , 2.0 μg/ml) and 66.6% of C. krusei isolates were resistant to itraconazole. Within each species there were no geographic differences in susceptibility to fluconazole or itraconazole.Keywords
This publication has 14 references indexed in Scilit:
- Candida parapsilosis Fungemia Associated with Implantable and Semi-Implantable Central Venous Catheters and the Hands of Healthcare WorkersDiagnostic Microbiology and Infectious Disease, 1998
- National Surveillance of Nosocomial Blood Stream Infection Due to Species of Candida Other than Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE ProgramDiagnostic Microbiology and Infectious Disease, 1998
- The Epidemiology of Hematogenous Candidiasis Caused by Different Candida SpeciesClinical Infectious Diseases, 1997
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of TransmissionClinical Infectious Diseases, 1996
- Fungemia: An increasing problem in a Danish university hospital 1989 to 1994Clinical Microbiology & Infection, 1995
- Antibiotic Resistance in ICUs: A Multifaceted Problem Requiring a Multifaceted SolutionInfection Control & Hospital Epidemiology, 1995
- In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution methodMycopathologia, 1995
- Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study GroupAntimicrobial Agents and Chemotherapy, 1995